Zerodha (Trading Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
Zerodha (Trading Account)
FREE Equity Delivery and MF
Flat ₹20/trade Intra-day/F&O
|
|
Eris Lifesciences IPO is a book built issue of Rs 1,741.16 crores. The issue is entirely an offer for sale of 2.89 crore shares.
Eris Lifesciences IPO bidding started from June 16, 2017 and ended on June 20, 2017. The allotment for Eris Lifesciences IPO was finalized on Friday, June 23, 2017. The shares got listed on BSE, NSE on June 29, 2017.
Eris Lifesciences IPO price band is set at ₹600 to ₹603 per share. The minimum lot size for an application is 24 Shares. The minimum amount of investment required by retail investors is ₹14,472.
The issue includes a reservation of up to 150,000 shares for employees offered at a discount of Rs 60 to the issue price.
Axis Capital Limited, Citigroup Global Markets India Private Limited and Credit Suisse Securities (India) Private Limited are the book running lead managers of the Eris Lifesciences IPO, while Link Intime India Private Ltd is the registrar for the issue.
Refer to Eris Lifesciences IPO RHP for detailed information.
| IPO Date | June 16, 2017 to June 20, 2017 |
| Listing Date | June 29, 2017 |
| Face Value | ₹1 per share |
| Price Band | ₹600 to ₹603 per share |
| Lot Size | 24 Shares |
| Total Issue Size | 28,875,000 shares (aggregating up to ₹1,741.16 Cr) |
| Offer for Sale | 28,875,000 shares of ₹1 (aggregating up to ₹[.] Cr) |
| Employee Discount | Rs 60 per share |
| Issue Type | Book Built Issue IPO |
| Listing At | BSE, NSE |
| Share holding pre issue | 137,500,000 |
| Share holding post issue | 137,500,000 |
Eris Lifesciences IPO offers 15,948,750 shares. 8,617,500 (54.03%) to QIB, 4,308,750 (27.02%) to NII, 2,872,500 (18.01%) to RII, 150,000 (0.94%) to employees. 119,687 RIIs will receive minimum 24 shares and (sNII) and (bNII) will receive minimum 336 shares. (in case of oversubscription)
| Investor Category | Shares Offered | Maximum Allottees |
|---|---|---|
| Anchor Investor Shares Offered | - | NA |
| QIB Shares Offered | 8,617,500 (54.03%) | NA |
| NII (HNI) Shares Offered | 4,308,750 (27.02%) | |
| Retail Shares Offered | 2,872,500 (18.01%) | 119,687 |
| Employee Shares Offered | 150,000 (0.94%) | NA |
| Total Shares Offered | 15,948,750 (100%) |
Eris Lifesciences IPO opens on June 16, 2017, and closes on June 20, 2017.
| IPO Open Date | Friday, June 16, 2017 |
| IPO Close Date | Tuesday, June 20, 2017 |
| Basis of Allotment | Friday, June 23, 2017 |
| Initiation of Refunds | Tuesday, June 27, 2017 |
| Credit of Shares to Demat | Wednesday, June 28, 2017 |
| Listing Date | Thursday, June 29, 2017 |
| Cut-off time for UPI mandate confirmation | 5 PM on June 20, 2017 |
Investors can bid for a minimum of 24 shares and in multiples thereof. The below table depicts the minimum and maximum investment by retail investors and HNI in terms of shares and amount.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 24 | ₹14,472 |
| Retail (Max) | 13 | 312 | ₹188,136 |
| Lot Size Calculator | |||
Incorporated in 2007, Eris Lifescience Ltd is Ahmedabad, Gujrat based pharmaceutical company engaged in research, development, manufacturing and selling of select therapeutic areas within the chronic and acute categories of the Indian Pharmaceutical Market.
Eris product portfolio is primarily focused on therapeutic areas which require the intervention of super specialist and specialist doctors such as Diabetologists, Endocrinologists Cardiologists, and Gastroenterologists.
Eris products in the chronic category cater primarily to the therapeutic areas including cardiovascular, anti-diabetics and neurology, chronic respiratory and chronic pain (analgesics).
In acute category, the product portfolio includes vitamins, gastroenterology, anti-infectives, gynaecology, cute respiratory, acute pain (analgesics), hepatoprotectives, hormones, hematology, dermatology, anti-obesity products and products for injury healing.
Eris Lifescience own and operate a manufacturing facility in Guwahati, Assam. They also outsource the manufacturing of certain of its products to 20 manufacturers. Eris strong sales team comprised of 1,310 marketing representatives.
Eris Lifescience Strengths:
• Focus on branded prescription based pharmaceutical products catering to lifestyle related disorders
• Portfolio of high volume and leading brands
• Focus on metro cities and class 1 towns in India which have higher incidence of lifestyle disorders and concentration of specialists and super specialists
• Multi-faceted product selection and engagement model leading to growth in prescription
• Strong sales, marketing and distribution capabilities
| Particulars | For the year/period ended (in Rs. Million) | |||||
|---|---|---|---|---|---|---|
| 31-Mar-16 | 31-Mar-15 | 31-Mar-14 | 31-Mar-13 | 31-Mar-12 | ||
| Total Assets | 3,973.59 | 3,572.85 | 2,705.99 | 1,718.05 | 1,019.67 | |
| Total Revenue | 5,970.21 | 5,455.58 | 5,088.22 | 3,930.64 | 2,739.40 | |
| Profit After Tax | 1,348.58 | 892.59 | 709.12 | 584.40 | 370.63 | |
The objects of the Offer are:
1. To achieve the benefits of listing the Equity Shares on the Stock Exchanges and
2. For the sale of up to 28,875,000 Equity Shares by the Selling Shareholders.
[Dilip Davda] Investors may consider investment for medium to long term in this niche player having better penetration. Read detail review...
The Eris Lifesciences IPO is subscribed 3.29 times on June 20, 2017 5:00:00 PM. The public issue subscribed 3.51 times in the retail category, 4.68 times in the QIB category, and 0.45 times in the NII category. Check Day by Day Subscription Details (Live Status)
| Category | Subscription (times) |
|---|---|
| QIB | 4.68 |
| NII | 0.45 |
| Retail | 3.51 |
| Employee | 0.86 |
| Total | 3.29 |
| Listing Date | June 29, 2017 |
| BSE Script Code | 540596 |
| NSE Symbol | ERIS |
| ISIN | INE406M01024 |
| Final Issue Price | ₹603 per share |
| Price Details |
|---|
| Final Issue Price |
| Open |
| Low |
| High |
| Last Trade |
| BSE |
|---|
| ₹603.00 |
| ₹612.00 |
| ₹592.30 |
| ₹627.70 |
| ₹601.05 |
| NSE |
|---|
| ₹603.00 |
| ₹611.00 |
| ₹593.25 |
| ₹628.00 |
| ₹601.50 |
Eris Lifesciences Limited
7th Floor, Commerce House IV,
Beside Shell Petrol Pump, 100 Feet Road,
Prahladnagar, Ahmedabad 380 015
Phone: +91 79 3045 1111
Email: complianceofficer@erislifesciences.com
Website: http://eris.co.in/
Link Intime India Private Ltd
Phone: +91-22-4918 6270
Email: eris.ipo@linkintime.co.in
Website: https://linkintime.co.in/initial_offer/public-issues.html
Eris Lifesciences IPO is a main-board IPO of 28,875,000 equity shares of the face value of ₹1 aggregating up to ₹1,741.16 Crores. The issue is priced at ₹600 to ₹603 per share. The minimum order quantity is 24 Shares.
The IPO opens on June 16, 2017, and closes on June 20, 2017.
Link Intime India Private Ltd is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
The Eris Lifesciences IPO opens on June 16, 2017 and closes on June 20, 2017.
Eris Lifesciences IPO lot size is 24 Shares, and the minimum amount required is ₹14,472.
You can apply in Eris Lifesciences IPO online using either UPI or ASBA as payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO application is offered by brokers who don't offer banking services. Read more detail about apply IPO online through Zerodha, Upstox, 5Paisa, Nuvama, ICICI Bank, HDFC Bank and SBI Bank.
The finalization of Basis of Allotment for Eris Lifesciences IPO will be done on Friday, June 23, 2017, and the allotted shares will be credited to your demat account by Wednesday, June 28, 2017. Check the Eris Lifesciences IPO allotment status.
Useful Articles
FREE Intraday Trading (Eq, F&O)
Flat ₹20 Per Trade in F&O
|
|
RHP
IPO Mentor (700+ Posts, 900+ Likes)
IPO Guru (2600+ Posts, 2700+ Likes)
i am lucky that i did not get allotment in shipyard...lets see what happens after listing...